Thanks to LinkedIn for supporting industry focus.

LinkedIn jobs uses knowledge of both hard and soft scales to match you with the people who

fit your role the best.

Post a job today at LinkedIn.com slash get $50 off your first job post.

Welcome to Industry Focus, the show that dives into a different sector of the stock market every single day.

Today is Wednesday, August the 14th and we're talking health care.

I'm your host Shannon Jones and I am joined via Skype by health care guru Todd Campbell Todd how's it going

Good I'm really excited to talk about some really high profile interesting stories here

that I'm sure our listeners are just going to absolutely be enthralled with, right?

And it's not just these stories because Todd, I mean when you look back over the past week,

the news across the biotech space has just been massive.

So many things happening.

Of course, most I think are snafu's more of the negative sort.

But I think with today's show, I'm excited because we've kind of

sifted through many of the major headlines that are going on right now to the two

biggest stories that I think investors need to focus on so we've got to first up, Novartis, once again making the

scandals headlines, unfortunately for them. And then we'll also dive into MNA on the cancer diagnostics front. Todd, let's just kick it off with Novartis.

This is a gene therapy story we've been following really closely, especially leading up to the approval of their landmark gene therapy drug.

Of course, Novartis is ticker symbol, NVS.

And this is in relation to Novartis and Vexus and their drug that was approved back in May.

First gene therapy approved for a very rare but serious genetic condition.

We've learned that basically the data supporting the

...